Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT03471793
Recruiting Observational

The Australian Colonic Large Sessile Lesion Endoscopic Resection Study

NCT03471793 · tracked via the Priya Life Science Australia tracker
Sponsor
Western Sydney Local Health District
Phase
Observational
Started
2017-02-24
Last updated
2025-03-27

Condition(s) studied

Colon AdenomaColon Polyp

Study summary

A prospective, multicentre, observational study of all patients referred for endoscopic resection of sessile colorectal polyps sized ≥20 mm conducted with intention to treat analysis

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Patients referred for endoscopic resection of a large sessile colonic polyp or laterally spreading tumour ≥20mm in size. * Able to give informed consent to involvement in the clinical study Exclusion Criteria: * Unable to provide informed consent for involvement

Primary outcome measure(s)

  • Recurrence — 6-60months
    Follow up colonoscopies as per standard of care for 6 - 60 months noting and treating any recurrence.

Trial sites (1)

FacilityCityRegionStatus
Westmead Endoscopy Unit Westmead New South Wales Recruiting

More Western Sydney Local Health District trials in Australia

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers Recruiting
GENomic Predictors in A Multi-Ethnic Population With Kidney Disease Study Enrolling by invitation
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD) Recruiting
Australian Genomics Of Chronic Allograft Dysfunction Study Recruiting
Cold Snare Endoscopic Mucosal Resection (EMR) vs Cold EMR With Margin Snare Tip Soft Coagulation (STSC) Recruiting

Other trials for the same condition

Cold Snare Endoscopic Mucosal Resection (EMR) vs Cold EMR With Margin Snare Tip Soft Coagulation (STSC) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03471793 on ClinicalTrials.gov ↗ ← All trials in Australia